It’s already April – time flies when you’re busy and we have continued to progress our trial and meeting programmes in the first three months of this year. The PEARL study (evaluating early referral to palliative care) will open to recruitment imminently; and study start-up activities are proceeding for OSCILLATE (alternating osimertinib and gefitinib). We have also received confirmation of a new trial that will be going ahead this year – ALTG 16/004 SCRIBE in small cell lung cancer – congratulations to Paul Mitchell and the rest of the team on this achievement.
Applications for this year’s Preceptorship in Lung Cancer will open in the next few weeks so please highlight this excellent learning and mentoring opportunity to your trainee and early consultant colleagues. The Preceptorship date is October 6 and 7, in Melbourne.
For this year’s ALTG Lung Cancer Symposium Paul Mitchell has taken on the role of Symposium Chair and we have selected the Westin Sydney hotel as the venue. The Symposium follows the WCLC and the organising committee has already set aside time in the agenda to incorporate the latest news from the Yokohama conference. Our second ALTG Members’ Meeting of the year and a Shine A Light on Lung Cancer dinner event will be held on the day prior to the Symposium, so mark November 24 and 25 in your diaries for a trip to Sydney. For those who missed out on last year’s Symposium, or who would like to revisit the talks, we have established an ALTG Virtual Library where members can access videos of each speaker.
Finally, I hope to see many of you at our next ALTG Members’ Meeting at the Parkroyal Melbourne hotel on Friday 12th May. Contact Ros (firstname.lastname@example.org) for more information or go to the Events article in this newsletter to access the online registration form.